ATE541935T1 - Wachstumshormon fusionprotein - Google Patents

Wachstumshormon fusionprotein

Info

Publication number
ATE541935T1
ATE541935T1 AT02806858T AT02806858T ATE541935T1 AT E541935 T1 ATE541935 T1 AT E541935T1 AT 02806858 T AT02806858 T AT 02806858T AT 02806858 T AT02806858 T AT 02806858T AT E541935 T1 ATE541935 T1 AT E541935T1
Authority
AT
Austria
Prior art keywords
growth hormone
fusion protein
hormone fusion
modified
binding domain
Prior art date
Application number
AT02806858T
Other languages
English (en)
Inventor
Richard Ross
Jon Sayers
Peter Artymiuk
Original Assignee
Asterion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asterion Ltd filed Critical Asterion Ltd
Application granted granted Critical
Publication of ATE541935T1 publication Critical patent/ATE541935T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
AT02806858T 2001-12-14 2002-12-06 Wachstumshormon fusionprotein ATE541935T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0130052A GB2384001B (en) 2001-12-14 2001-12-14 Chimeric growth hormone-growth hormone receptor proteins
PCT/GB2002/005523 WO2003070765A2 (en) 2001-12-14 2002-12-06 Growth hormone fusion protein

Publications (1)

Publication Number Publication Date
ATE541935T1 true ATE541935T1 (de) 2012-02-15

Family

ID=9927705

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02806858T ATE541935T1 (de) 2001-12-14 2002-12-06 Wachstumshormon fusionprotein

Country Status (19)

Country Link
US (2) US7524649B2 (de)
EP (2) EP1456385B1 (de)
JP (2) JP5248734B2 (de)
KR (3) KR100848802B1 (de)
CN (2) CN100558899C (de)
AT (1) ATE541935T1 (de)
AU (1) AU2002366325B2 (de)
CA (1) CA2468439A1 (de)
ES (1) ES2378424T3 (de)
GB (2) GB2384001B (de)
HU (1) HUP0402496A3 (de)
IL (3) IL162433A0 (de)
MX (1) MXPA04005675A (de)
NZ (1) NZ533550A (de)
PL (1) PL210714B1 (de)
RU (2) RU2346047C2 (de)
SG (1) SG160205A1 (de)
WO (1) WO2003070765A2 (de)
ZA (2) ZA200404488B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2447632C (en) * 2000-06-16 2011-08-02 Asterion Limited Fusion protein agonist comprising a growth hormone binding portion and an external domain of a growth hormone receptor
GB2384001B (en) * 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
MX2007001180A (es) * 2004-07-26 2007-04-13 Asterion Ltd Enlazantes.
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
GB0606946D0 (en) * 2006-04-06 2006-05-17 Asterion Ltd Polypeptide antagonist
GB0618082D0 (en) * 2006-09-14 2006-10-25 Asterion Ltd Growth factor
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
GB0717985D0 (en) * 2007-07-20 2007-10-24 Asterion Ltd Growth hormone fusion proteins
GB0719818D0 (en) * 2007-10-11 2007-11-21 Asterion Ltd Growth hormone fusion polypeptides
WO2009077731A2 (en) * 2007-12-19 2009-06-25 Asterion Limited Prolactin fusion proteins
WO2011085070A2 (en) * 2010-01-06 2011-07-14 Virginia Tech Intellectual Properties, Inc. Methods and compositions to improve the health of plants, animals and microbes by manipulating protein entry into symbionts and their hosts
JP5412323B2 (ja) 2010-02-26 2014-02-12 日東電工株式会社 貼付製剤
GB201104285D0 (en) 2011-03-15 2011-04-27 Asterion Ltd Modified receptor fusion proteins
EP2606908A1 (de) 2011-12-19 2013-06-26 Ipsen Pharma S.A.S. Neuartige pharmazeutische Zusammensetzung für ein lang wirkendes Wachstumshormonfusionsprotein (LAGH)
AU2013214698B2 (en) * 2012-02-03 2017-02-16 Antisense Therapeutics Ltd Combination therapy comprising a growth hormone variant and an oligonucleotide targeted to the growth hormone receptor
JP2016511275A (ja) * 2013-03-11 2016-04-14 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン化合物
EP3303380B1 (de) 2015-06-02 2020-01-15 Novo Nordisk A/S Insuline mit polaren rekombinanten erweiterungen
WO2017055582A1 (en) 2015-10-01 2017-04-06 Novo Nordisk A/S Protein conjugates
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
WO2020014307A1 (en) * 2018-07-11 2020-01-16 Ohio University Peptide-based inhibitors of growth hormone action and methods of the thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5958879A (en) * 1989-10-12 1999-09-28 Ohio University/Edison Biotechnology Institute Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal
NZ260103A (en) * 1990-11-30 1996-10-28 Bio Technology General Corp Somatotropin with alterations in the alpha-helix-1 region
WO1992010576A1 (en) * 1990-12-13 1992-06-25 The Upjohn Company Fusion polypeptides
ATE196548T1 (de) * 1991-05-10 2000-10-15 Genentech Inc Auswählen von agonisten und antagonisten von liganden
IT1251895B (it) * 1991-09-27 1995-05-26 Eniricerche Spa Mutanti dell'ormone della crescita umano e loro impiego
US5686268A (en) * 1992-06-19 1997-11-11 Pfizer Inc. Fused proteins
ATE455171T1 (de) 1995-09-21 2010-01-15 Genentech Inc Varianten des menschlichen wachstumshormons
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
DE69712124T2 (de) * 1996-02-13 2002-12-12 Jcr Pharmaceutical Co., Ltd. Hormones de croissance humaines mutantes et leur utilisation
ATE199570T1 (de) 1996-08-16 2001-03-15 Medical Res Council Selbst-replizierende episomale expressionsvektoren, welche gewebespezifische expression vermitteln
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
AU775937B2 (en) * 1999-01-14 2004-08-19 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CA2447632C (en) * 2000-06-16 2011-08-02 Asterion Limited Fusion protein agonist comprising a growth hormone binding portion and an external domain of a growth hormone receptor
GB2384001B (en) * 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins

Also Published As

Publication number Publication date
GB0130052D0 (en) 2002-02-06
IL162433A0 (en) 2005-11-20
JP2010043100A (ja) 2010-02-25
CN1604965A (zh) 2005-04-06
US20050123558A1 (en) 2005-06-09
IL162433A (en) 2011-09-27
AU2002366325A1 (en) 2003-09-09
WO2003070765A2 (en) 2003-08-28
EP1456385A2 (de) 2004-09-15
KR100879553B1 (ko) 2009-01-22
RU2008118104A (ru) 2009-11-20
GB0320479D0 (en) 2003-10-01
GB2384001A (en) 2003-07-16
GB2389115A (en) 2003-12-03
US7524649B2 (en) 2009-04-28
RU2346047C2 (ru) 2009-02-10
KR20040083470A (ko) 2004-10-02
HUP0402496A3 (en) 2012-03-28
ZA200404488B (en) 2006-03-29
SG160205A1 (en) 2010-04-29
CN100558899C (zh) 2009-11-11
CN101638437A (zh) 2010-02-03
IL200659A0 (en) 2010-05-17
JP5248734B2 (ja) 2013-07-31
KR100848802B1 (ko) 2008-07-28
CA2468439A1 (en) 2003-08-28
EP2365085A1 (de) 2011-09-14
KR20070108254A (ko) 2007-11-08
EP1456385B1 (de) 2012-01-18
HUP0402496A2 (hu) 2005-03-29
US20090239801A1 (en) 2009-09-24
RU2004117777A (ru) 2005-05-10
NZ533550A (en) 2006-02-24
AU2002366325B2 (en) 2008-04-24
WO2003070765A3 (en) 2003-11-27
ES2378424T3 (es) 2012-04-12
GB2389115B (en) 2005-03-16
PL210714B1 (pl) 2012-02-29
GB2384001B (en) 2004-02-04
ZA200600149B (en) 2006-10-25
KR20060106862A (ko) 2006-10-12
MXPA04005675A (es) 2005-04-19
JP2005525106A (ja) 2005-08-25
HK1070669A1 (en) 2005-06-24
PL371313A1 (en) 2005-06-13

Similar Documents

Publication Publication Date Title
IL200659A0 (en) Modified polypeptide
DE60040225D1 (en) Erythropoietin immunglobulin fusionsproteine
BR0212256A (pt) Proteìnas de fusão de transferrina modificadas
DE60333306D1 (de) Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen
PL336306A1 (en) Proteinous fusions of tgf-beta ii type receptor with a constant immunoglobulin area
NO20030443D0 (no) Fremgangsmåte for fremstilling av funksjonelle proteindomener
DE60325892D1 (de) Stellungs- und verwendungsverfahren
ATE353921T1 (de) Chimäre polypeptide, verfahren zur herstellung und verwendung dafür
PL2241575T3 (pl) Polipeptydy fuzyjne IGF-1 oraz ich zastosowania terapeutyczne
DK1129186T3 (da) Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
EE05590B1 (et) Neurotroopsed tegurid
IL146451A0 (en) C-terminal protein tagging
EP1539809A4 (de) Hcv-fusionsproteine mit modifizierten ns3-domänen
EP1523492A4 (de) Igg-fc/hiv-gp120/c3d-fusionsprotein
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
EP1385532A4 (de) Stimulation der osteogenese mit rang-ligandenfusionsproteinen
DE69927375D1 (de) Fusionsprotein mit direkter verknüpfung des il-6-rezeptors mit il-6
DK1171470T3 (da) Antistoffer over for placentaprotein 13
ATE328003T1 (de) Chimäre nukleinsäuren und polypeptide aus lyssavirus
NO20021244D0 (no) Subenhet-optimaliserte fusjonsproteiner
WO2004005335A3 (en) Multimerised growth hormone fusion proteins
ATE404576T1 (de) Neuartiges polypeptid und dessen kodierende nukleinsäuren
ATE480262T1 (de) Fusionsproteine